Skip to content
OpenCapital
Get started

Agios Pharmaceuticals AGIO Accrued research and development costs

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.16B+18.1%
Enterprise value$2.08B+15.2%
P/S32.7×-16.7×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%—
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%—
Debt / equity0×0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept agio:AccruedResearchAndDevelopmentCostsCurrent.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's accrued research and development costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's accrued research and development costs?
Agios Pharmaceuticals (AGIO) reported accrued research and development costs of $8.52M in Q1 2026.
How has Agios Pharmaceuticals's accrued research and development costs changed year-over-year?
Agios Pharmaceuticals's accrued research and development costs decreased by 6.0% year-over-year, from $9.06M to $8.52M.
What is the long-term trend for Agios Pharmaceuticals's accrued research and development costs?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's accrued research and development costs has grown at a 17.3% compound annual growth rate (CAGR), from $5.44M to $12.08M.